Cancer-derived heat shock protein gp96 induces a tumorspecific protective immune response primarily mediated by cytotoxic T lymphocytes (CTL) directed toward cancerassociated peptides associated with gp96. Both innate and adaptive immune responses have been demonstrated using a cell culture-based signaling mechanism. When used as an extraneous vaccine, one critical interaction which must occur for an immune response to be generated is the interaction between gp96 and the antigen presenting cell (APC) surface receptors (CD91, SR-A, TLR-2, and TLR-4). Our previous study concluded that gp96 purified from various rat and human prostate cancers is differentially glycosylated based on the amino and neutral monosaccharide content, and it was postulated that the monosaccharides may play a role in its biological activity. In this report, we report differences in the cancer-specific sialic acid content of gp96 purified from normal rat prostate compared to two rat prostate cancers, MAT-LyLu and Dunning G, as well as between two human prostate cancer cells, LnCaP and DU145. We also examined the modulatory effect of sialic acid residues on the binding of gp96 to APCs and its subsequent activation. Our results supported the contention that significant differences in the sialic acid content exist between Dunning G, MAT-LyLu, and normal rat prostate gp96, which affected its binding and biochemical activity to APCs. We therefore postulate that varied glycans of HPS96, a hitherto neglected structural component, may play a pivotal role in its anticancer activity. We suggest that construction of the glycan tree is a key to identification of the necessary and sufficient elements in the structure-function activity of HSP96.
Introduction
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as heat shock proteins (HSP) (Srivastava et al. 1986; Srivastava and Maki 1991; Nicchitta et al. 2004; Yang and Li 2005) . The synthesis of gp96, as with other HSPs, is upregulated during cellular stress such as heat shock, glucose deprivation, bacterial and viral infections, and UV radiation exposure during which time gp96 becomes crucial in maintaining the structural integrity of misfolded proteins (Buchner 1999; Shin et al. 1999; Yang and Li 2005; Bukau et al. 2006) .
The functional property of gp96 to associate with proteins/ peptides has been exploited for its development as an autologous cancer vaccine, which has been observed and documented in many animal experiments as well as in human clinical trials (Srivastava 2006; Ciocca et al. 2007; Maki et al. 2007; Testori et al. 2008) . The tumor protective property of gp96 is dependent on two key events, both of which occur upon the interaction of gp96 with antigen presenting cell (APC) surface receptors. First, the interaction of gp96 with toll-like receptors (TLR-2 and TLR-4) results in APC activation which results in pro-inflammatory cytokine (TNFα, IL-1β, and IL-12) secretion (Basu et al. 2001; Vabulas et al. 2002; Wang et al. 2005; Warger et al. 2006; Huang et al. 2009 ) Second, the interaction of gp96 with CD91 and scavenger receptor-A (SR-A) leads to internalization of the gp96-peptide complex resulting in cross presentation of the gp96-associated peptide Binder and Srivastava 2004; De Filippo et al. 2008) . Cross presentation of the gp96-associated peptides by MHC class I results in a peptide-specific cytotoxic T lymphocyte (CTL)-mediated immune response (Suto and Srivastava 1995; Berwin and Nicchitta 2001) . Thus, the immune response generated by gp96 activates both the innate and adaptive arms of the immune system leading to an effective anti-tumor immune response.
Much effort has been invested into the issue of tissue-derived invariance of the gp96 protein and cDNA sequence but posttranslational modifications, such as glycosylation, have largely been understudied. Gp96 is a glycoprotein consisting of six potential N-linked glycosylation sites with no reports of O-linked glycosylation (Mazzarella and Green 1987; Maki et al. 1990; Cala 2000) . One common feature shared by both N-linked and O-linked glycan structures is ability to be terminally modified through sialylation or the addition of sialic acid (Helenius and Aebi 2001) . Sialic acid is a general term that refers to neuraminic acid that can be further modified by the addition of an acetyl group (N-acetylneuraminic acid (NANA)) or a glycolyl group (N-glycolylneuraminic acid (NGNA)) (Varki 1997) .
Sialic acid is an important terminal modification of glycans because the presence of sialic acid residues imparts a negative charge on the surface of the glycan thus impacting the potential to inhibit intermolecular and intercellular interactions as observed in various diseases (Varki 1997) . The most prominent biological effect of sialylation was demonstrated in one study in which sialylation of IgG was linked to inflammation associated with autoimmune diseases (Kaneko et al. 2006 ). Aberrant sialylation has further been observed to aid both in invasion and adhesion of various cancer cells as reported by several studies. In one of many studies focusing on sialylation and cancer, it was observed that in colon and breast cancer, the increased sialic acid content was correlated with cell attachment and migration thus contributing to the migratory and invasive phenotype of the cells (Orntoft and Vestergaard 1999; Lin et al. 2002; Seales et al. 2005) . The clinical relevance of aberrant sialylation was observed in one study in which sialic acid-specific lectins can serve as prognostic indicators as they can differentiate between various thyroid proliferative diseases solely on the basis of cell surface glycoprotein sialic acid content (Babal et al. 2006) . These studies have demonstrated the importance of the aberrant sialic acid content in various pathological diseases.
The clinical relevance of gp96 and the sialic acid residues of glycoproteins as described above provide evidence for the need to fully address the glycosylation status of gp96 and how it affects the physical properties of gp96. Our previous study focused on the N-linked glycosylation (neutral and amino sugars) of gp96 and concluded that glycosylation significantly differed between various rat and human prostate cancers (Suriano et al. 2005) . A recent study correlated sialylation of membranebound HSPs with stages of progression in fibrosarcoma cell lines (Avidan et al. 2009 ) suggesting that cancer-specific immune response may be critically dependent on sialic acid composition. This study demonstrates the significance of sialylation of cell membrane-bound gp96 and validates our finding of the varied sialic acid content of the purified gp96 immunogen, which is ER-resident and constitutes the bulk of cellular gp96 as compared to a small but distinct number of membrane-bound gp96 (Srivastava et al. 1986; Srivastava and Maki 1991; Avidan et al. 2009) .
In this report, we first aimed to determine if the gp96 Nlinked glycans are further modified through the addition of sialic acid, both NANA and NGNA. For this study, gp96 was purified from two human prostate cancers (androgen independent DU145 and androgen dependent LnCaP) and two rat prostate cancers (androgen independent/metastatic MAT-LyLu and androgen dependent/nonmetastatic Dunning G). The sialic acid content was determined by a highly sensitive method using high pH anion exchange chromatography with pulse amperometric detection (HPAE-PAD). Second, provided that the immune response generated by gp96 relies on the initial interaction of gp96 with APC surface receptors, which is a direct proteinprotein interaction, we wanted to assess the contribution, if any, of gp96's sialic acid residues on its ability to bind to and activate the APC, RAW 264.7. Since cancers are known to express aberrations in sialylation of glycoproteins, it is conceivable to speculate that aberrations in the sialic acid content of gp96 can affect its essential protein-protein interaction of binding to APC surface receptors thus affecting the immunogenic property of gp96.
Results

Purification of gp96 from tissues
Whole tumor tissues from rat and human origin, as well as a noncancerous rat prostate tissue, were used to purify gp96 for glycosylation studies. The whole tumor tissues used in the study are as follows: two transplantable rat prostate cancer tumors -Dunning G (nonmetastatic and androgen-dependent) and MAT-LyLu (metastatic and androgen-independent) and two transplantable human prostate cancer tumors -LnCaP (nonmetastatic and androgen-dependent) and DU145 (nonmetastatic and androgen-independent).
Since gp96 is an N-linked glycoprotein, a ConA-Sepharose column (5 mL) was used to selectively bind glycosylated proteins (specifically mannose and glucose residues) in order to separate them from nonglycosylated proteins. The glycosylated proteins eluted from the ConA column were then applied to a size exclusion PD-10 column for buffer exchange. Gp96 was finally purified on a DEAE-Sephacel column (5 mL). Seven equal volume fractions of 1.7 mL were collected from the DEAE column in which gp96 elutes in fractions 3 and 4. The purification of gp96 from all the tissues was monitored by resolving samples from all DEAE fractions on SDS-PAGE followed by Coomassie staining ( Figure 1A ). The majority of gp96 eluted in fraction 3 of the DEAE column with lesser amounts, approximately half the concentration of fraction 3, eluting in fraction 4 ( Figure 1A ). It is important to note that the gp96 used in our studies is purified by differential centrifugation of tumor tissues resulting in isolation of the majority of gp96, which is ER resident. The purification process of gp96 was monitored at various steps, through Western blotting and ConA-HRP, to assure that the majority of glycosylated gp96 was being purified. Also, from the literature as well as from our experience, purification of gp96 by an antibody or ConA produces comparable results.
The gp96 N-glycans are modified by sialic acid
Previous studies have documented that differences in glycosylation patterns of gp96, specifically in terms of the neutral and amino monosaccharides, exist between various gp96 samples (Suriano et al. 2005 ). This study is designed to examine differences in the sialic acid content of gp96. The terminal location of sialic acid residues facilitates their release through the use of neuraminidase and does not require the harsh acid conditions needed to release neutral monosaccharides (TFA) and amino monosaccharides (HCl). Neuraminidase, commonly referred to as sialidase, facilitates the release of both NANA and NGNA from the glycan structure (Rohrer et al. 1998 ) and complete removal of both NANA and NGNA residues from all three rat samples was assessed through Western blot analysis followed by LFA (Limax flavus) lectin analysis. The LFA lectin is specific for neuraminic acid, irrespective of the linkage by which neuraminic acid is attached to monosaccharides of the glycan structure (Miller et al. 1982) . LFA was able to detect sialylated gp96 only in the samples which were not incubated with neuraminidase as opposed to the samples which were incubated with neuraminidase in which gp96 was not detected (1B). This assured that the neuraminic acid residues were cleaved from gp96 and could be subsequently analyzed by HPAE-PAD. In parallel, the gp96 samples were incubated without neuraminidase and subsequently resolved by SDS-PAGE followed by Coomassie staining to confirm that gp96 was present in all samples (1C).
Diversification of the gp96 N-linked glycans by sialic acid
HPAE-PAD has also been used as a sensitive method to quantitate the sialic acid content of glycoproteins (Rohrer et al. 1998 ). Gp96 from all three rat tissues (normal prostate, Dunning G, and MAT-LyLu) as well as from both human tissues (LnCaP
Sialylation of gp96
Fig. 1. Gp96 purified from tissues is sialylated. The purification of gp96 from tumor homogenates was monitored at each purification step by Coomassie staining of SDS-PAGE gels. Pure gp96 eluted in fractions 3 and 4 from the DEAE sephacel column as shown in the Coomassie stained SDS-PAGE gel (A). Sialylation and Desialylation of gp96 were monitored by Western blot analysis using the N-acetylneuraminic (NANA) and N-glycolylneuraminic acid-specific lectin, LFA. MAT-LyLu, Dunning G, and normal prostate gp96 samples not treated with sialidase were detected by LFA as opposed to gp96 samples incubated with sialidase which were not detected by LFA (B). Coomassie staining of SDS-PAGE gels was used as a control and confirmed that gp96 was present in all lanes (C). and DU145) were assayed for N-acetylneuraminic acid and N-glycolylneuraminic acid. For both human and rat gp96 samples, three HPAE-PAD chromatograms obtained from each sample appeared similar to each other indicating the reproducible nature of this analysis. For total sialic acid quantitation, all three sets of PAD profiles, including the two that are not shown, were used for determination of both N-acetylneuraminic acid (NANA) and N-glycolylneuraminic acid (NGNA) content of the various human and rat gp96 samples based on the standard chromatogram in which each peak corresponds to 100 pmol. As an internal standard, KDN (3-deoxy-D-glycero-D-galacto-2-nonulosonic acid) was used because it elutes in between NANA and NGNA and was not used for any quantification purposes. Student's paired t-test analyses were also performed to determine if differences in monosaccharide concentrations were statistically significant (P < 0.05) between two gp96 samples.
A qualitative comparison of the gp96 sialic acid chromatograms for all three rat samples ( Figure 2A ) and both human samples ( Figure 2B ) displayed a similar NANA (single asterisk) and NGNA (double asterisk) profile. Quantification of NANA and NGNA is shown in the bar chart in Figure 3 , and the actual concentration (pmol/μg gp96) of both NANA and NGNA is reported in Table I . NANA concentrations increase from normal prostate (195.5) to MAT-LyLu (245.7) and subsequently decrease in Dunning G (116.9). NGNA decreased from normal prostate (39.9) to MAT-LyLu (28.6) to Dunning G (11.5). Statistically significant differences (P < 0.05), indicated by the asterisks, were observed when comparing NANA from all three rat prostate tissues (prostate versus MAT-LyLu, prostate versus Dunning G, and Dunning G versus MAT-LyLu). Differences in NGNA concentrations were also statistically significant among all three rat gp96 samples. When comparing the two human prostate cancers, a statistically significant difference was observed in NANA between DU145 (161.1) and LnCaP (178). NGNA was not detected in LnCaP as opposed to DU145 (8.9). Although we assayed for the presence of both NANA and NGNA, the emphasis should be placed on NANA because it is still controversial, especially in humans, if and when NGNA is expressed and under what circumstances (Varki 2001) .
Desialylation of gp96 enhances binding to the antigen presenting cell, RAW 264.7
The interaction between gp96 and APC surface receptors is a critical protein-protein interaction which occurs and is responsible for activation of both the innate and adaptive arms of the immune system required for an effective tumor protective response. Therefore, because it is known that sialic acid residues affect protein-protein interactions, we next wanted to investigate if the sialic acid residues of the gp96 N-glycans modulate binding to the APC RAW 264.7, which has documented to express all known receptors (SR-A, CD91, TLR-2, and TLR-4) to which gp96 binds (Müller et al. 2001; Berwin et al. 2003; Binder and Srivastava 2004; Yu et al. 2006) . For this study, enzymatically desialylated gp96 purified from both human prostate cancers R Suriano et al.
Fig. 2.
Chromatograms representing the sialic acid content of neuraminidase treated gp96. Each of the chromatograms is labeled on the right according to the tissue source. The peaks represent the two main sialic acid monosaccharides, N-acetylneuraminic acid (indicated by one asterisk), and N-glycolylneuraminic acid (indicated by two asterisks), as well as KDN which is an internal standard which elute from the P10 column according to their retention time represented in minutes versus charge (nC). The sialic acid monosaccharides of interest were compared to the reference sialic acid standard chromatogram. Qualitatively, differences in the sialic acid content can be seen between normal rat prostate versus nonmetastatic Dunning G versus metastatic MAT-LyLu (A). Gp96 from both human samples, LnCaP and DU145, did not display visible differences (B). Shown in this figure is a representative of the sialic acid profile of one gp96 hydrolysate from each tissue/tumor.
(LnCaP and DU145) and from all the rat tissues (MAT-LyLu, Dunning G, and normal rat prostate) were incubated with RAW 264.7 cells. Binding of gp96 to RAW 264.7 was monitored by whole cell ELISA as described in Material and methods. Overall, an increase in cell surface binding was observed for all the gp96 samples upon desialylation. Comparing the human prostate cancer gp96 samples, LnCaP displayed a 22% increase in cell surface binding and DU145 displayed an 11% increase in cell surface binding upon desialylation (Figure 4) . The most significant differences were noted between the rat gp96 samples. Upon desialylation of gp96, RAW 264.7 receptor binding increased by 40% in prostate, 70% in Dunning G, and 60% in MAT-LyLu (Figure 4) . With the exception of DU145, all the purified Gp96 samples displayed a statistically significant (P < 0.05) increase in binding to RAW 264.7 upon desialylation. The results obtained are not surprising provided that, as already mentioned, it is very well documented that sialic acid has the potential to interfere with protein-protein interactions (Le Marer and Stehelin 1995; Varki 1997; Zhu et al. 2001 ).
Desialylation of gp96 modulates expression of secreted cytokines from RAW 264.7
As already mentioned, one key property of gp96 is its ability to induce cytokine secretion from antigen presenting cells (Basu et al. 2000; Reed et al. 2003; Warger et al. 2006; De Filippo et al. 2008; Huang et al. 2009 ). Therefore, in an initial approach to ascribe a function to the observed increased binding of desialylated gp96 to RAW 264.7, we investigated whether activation of RAW 264.7 is affected. Activation of RAW 264.7 was measured through the secretion of cytokines, which were detected by using membrane-based antibody cytokine arrays. Of 32 possible cytokines assayed for on the membrane, differences in expression levels were detected for 18 cytokines. Comparative cytokine levels were computed based on densitometry values normalized to the positive controls supplied by the manufacturer. The fold change between normal gp96 and desialylated gp96 is reported in Table II with values in bold indicating cytokines in which the fold change was greater than 1.5. In general, gp96 was able to activate RAW 264.7 macrophages with the majority Sialylation of gp96 Fig. 3 . Quantification of gp96 sialic acid from rat and human purified tumor tissues. The sialic acid monosaccharides were quantified with respect to the peaks obtained by the standards, each standard monosaccharide representing 100 pmol. N-Acetylneuraminic (NANA) acid is represented in black and N-glycolylneuraminic acid (NGNA) in gray. Statistically significant differences, indicated by the ( * ) (P < 0.05) in NANA were observed between rat prostate versus metastatic MAT-LyLu, rat prostate versus nonmetastatic Dunning G, and metastatic MAT-LyLu versus nonmetastatic Dunning G. Statistically significant differences in NANA were also observed between androgen-dependent LnCaP versus androgen-independent DU145. NANA and NGNA concentrations are in pmol/μg of gp96 ± SD obtained from three separate gp96 hydrolysates per tissue/tumor. (Figure 2A and B).
of cytokines decreasing in expression in macrophages incubated with desialylated gp96 compared to normal gp96. The cytokines, in which change in expression levels were detected, ranged from various inflammatory cytokines, such as TNFα, to chemotactic cytokines, such as GM-CSF. Our data not only confirm that gp96 activates RAW 264.7 macrophages but also that the sialic acid residues present on the gp96 N-glycans can modulate the expression of various secreted cytokines. As a positive control, we assayed for cytokines from macrophages stimulated with E. coli LPS (1 μg/mL) as well as subtracted any background obtained in cytokine expression from the complete DMEM media used. In order to rule out endotoxin as the source of RAW 264.7 activation, the LAL assay was conducted on purified preparations of gp96. The endotoxin content of our gp96 preparations was less than 0.5 EU/mg which was acceptable according to previously published reports (Basu et al. 2000; Warger et al. 2006; Huang et al. 2009 ). (20 μg) ± sialic acid from MAT-LyLu (MLL), Dunning G, normal rat prostate, DU145, and LnCaP were incubated with 5 × 105 RAW 264.7 cells. Statistically significant differences of gp96 binding to RAW 264.7 cell surface receptors were observed between all rat gp96 samples upon desialylation (P < 0.05), which is indicated by an asterisk. The human gp96 samples did not display statistically significant differences. The experiment shown is representative of three separate experiments with the standard deviation computed as n = 3. The fold change is a representative of the densitometry values calculated for each cytokine present on the array with respect to the internal positive control. Cytokines with fold changes above 1.5 are in bold.
Discussion
Gp96 is an essential molecular chaperone as evidenced by maintaining the integrity of proteins during times of cellular stress (Yang and Li 2005) . This ability to associate with cellular peptides/proteins is key to the development and use of gp96 as an autologous cancer vaccine (Blachere et al. 1997) . The immunogenicity of gp96 is dependent not only on the peptides it chaperones but also on one key event that occurs upon binding of gp96 to its APC surface receptors (SR-A, CD91, TLR-2, and TLR-4), which is at the core to initiating a tumor-specific innate and adaptive immune response (Vabulas et al. 2002; Berwin et al. 2003; Binder and Srivastava 2004; Wang et al. 2005) . One key property of gp96 is that it is post-translationally modified by N-linked glycosylation on six potential Asn residues (Maki et al. 1990; Cala 2000) . Glycan structures are not only responsible for introducing heterogeneity amongst proteins but also govern intermolecular and intramolecular interactions (Hart 1992; Kodama et al. 1993; Nalivaeva and Turner 2001) . With respect to glycosylation, one important modification of the glycan structures occurs by the addition of neuraminic acid to the terminal monosaccharide residues. Neuraminic acid can either be modified by the addition of an acetyl group, known as N-acetylneuraminic acid (NANA), or a glycolyl group, known as N-glycolylneuraminic acid (NGNA) (Varki 1997) . Regardless of its modification, neuraminic acid is commonly referred to as sialic acid. The presence of sialic acid on the surface of the glycan structures can have profound effects on protein-protein interactions due to the negative charge contributed by the sialic acid residues (Varki 1997) . The importance of sialic acid on protein-protein interactions was documented in one study in which the presence of sialic acid residues, on the N-linked glycan structures present on IgG, have the potential to affect the inflammatory properties observed during auto-immune diseases. It was shown that the absence of sialic acid allows IgG to bind stronger to its receptor on antigen presenting cells thus increasing signaling and hence synthesis of inflammatory cytokines (Kaneko et al. 2006 ). In the case of gp96, binding affinity of gp96 (± sialic acid) is also dependent on its underlying glycan composition as well as how many of the presumed six N-glycosylation sites are being used either preferentially or cumulatively.
Recently, membrane-bound gp96 was shown to be sialylated in fibrosarcoma cells and increased sialylation was observed in progressively growing cells. Although this study is the first to claim that gp96 is sialylated, it restricts itself to membranebound gp96 and does not address the sialylation status of the predominant cellular gp96 which is ER resident. Not only was our lab the first to discover that gp96 purified from various rat and human prostate cancers is differentially glycosylated (Suriano et al. 2005 ) but we also discovered that the ER-resident gp96 N-glycans, as per this study, are modified through the addition of sialic acid. In this study, we detected sialylated gp96 via the NANA and NGNA-specific LFA (Limax flavus) lectin as well as accurately quantitated the NANA and NGNA concentrations by HPAE-PAD.
When comparing the NANA concentrations in the rat gp96 samples, interesting and correlative differences were observed between various prostate cancer tissues. For instance, the highly metastatic MAT-LyLu expressed the highest concentration of NANA with respect to the nonmetastatic Dunning G and normal rat prostate. This increased sialic acid content corresponds to published reports in which metastatic cancers are highly correlated with the increased sialic acid content as a means of gaining motility and subsequently resulting in metastasis (Le Marer and Stehelin 1995; Orntoft and Vestergaard 1999; Zhu et al. 2001 ). While no difference was observed between LnCaP and DU145, it could possibly reflect the fact that neither of the two human prostate cancers is metastatic. It is important to mention that the above observations, correlating sialic acid with cancer cell metastasis, were made based on cell surface sialylated glycoproteins of cells which may or may not hold true for intracellular glycoproteins such as gp96. The high sialic acid content of ER-resident intracellular gp96 in the hormoneindependent and aggressive metastatic MAT-LyLu may be a validation of the sialic acid content associated with cell surface glycoproteins.
Having observed that the gp96 N-glycans are modified by sialic acid, we next wanted to determine if enzymatic removal of sialic acid, hence the overall glycan negative charge, from gp96 would affect its ability to bind to APC surface receptors. Interestingly, all gp96 samples analyzed displayed increased binding upon desialylation to the APC RAW 264.7 surface receptors. Although we did not determine to which receptor or receptors the increased binding of gp96 to RAW 264.7 occurs, the fact that desialylation of gp96 alters secretion of various key cytokines with respect to control gp96 suggests that gp96 may be interacting with signaling receptors such as the toll receptors (TLR-2 and TLR-4) but, this does not rule out the possibility that increased binding of desialylated gp96 occurs via the internalization receptors (CD91 and SR-A) as well.
The determination of the preferential use of a specific receptor is challenging since the prevalent reagent, be it antibodies or specific transcriptional inhibitors, cannot fully inhibit the signal transduction readouts used in these assays. Nevertheless, it is clear that desialylated gp96 has a decreased propensity for macrophage activation and as such attempts to use recombinant gp96 have to address this significant post-translational modification in defining its affinity and subsequent APC activation. The cytokine profile of gp96-mediated activation of APCs testifies the ability of the APCs to perform multi-cellular functions which are not limited to activation of the APCs per se but mediate other maturation functions that require modulation of angiogenesis (VEGF, thrombopoetin) and stimulation of the bone marrow myeloid cells (GM-CSF). Further studies are required in other cell systems with the comparable sialic acid content to fully elucidate the functional significance of the repertoire of induced cytokines/chemokines.
With respect to gp96 and APC activation, one valid concern which arises frequently is whether APC's are activated by gp96 or possible contaminating LPS. Various studies (Basu et al. 2000; Warger et al. 2006; Huang et al. 2009 ), including ours, were able to purify gp96 with low endotoxin levels (<0.5). In addition, Huang et al. also demonstrated that using polymyxin B on gp96 preparations had no effect on macrophage activation by gp96 as well as heating and proteinase K reduced macrophage activation by gp96 but not by LPS. Collectively, these observations suggest that macrophage activation by gp96 is not mediated by endotoxin. Further, the differential repertoire of cytokines induced by LPS and gp96 partially validate their distinct identities; however, this issue has been one of constant debate which has resulted in extreme care in the use of endotoxin-free reagents.
One key property which must be kept in mind when studying sialylation of gp96 is that there are six potential N-linked glycosylation sites, as mentioned, but it is not known if all six are glycosylated and hence sialylated. It may also be that sialylated glycans at one particular Asn residue governs protein-protein interactions while other sialylated glycans have no impact. This assumption may help to explain as to why the rat gp96 samples displayed a greater significant binding to APC surface receptors upon desialylation as opposed to the human gp96 samples.
Therefore, a detailed study needs to be undertaken in order to determine the position of the sialylated glycans and how they interact with the APC surface receptor(s). Also, it is of importance to determine if any biological effect is attributed to the increased binding of desialylated gp96 to APC surface receptors, which may very well alter how gp96 can be used as an immunogen and hence a vaccine.
Material and methods
Growth of cell lines in vitro and in vivo
The five cell lines that have been used for this project are: (1) DU145 (ATCC) -androgen-independent human prostate cancer cell line, (2) LnCaP (ATCC) -androgen-dependent human prostate cancer cell line, (3) MAT-Ly-Lu (ATCC) -androgen-independent rat prostate cancer cell line, (4) Dunning G (ATCC) -androgen-dependent rat prostate cancer cell line, (5) RAW 264.7 -murine macrophage cell line. The cell lines were cultured in either RPMI 1640 medium (prostate cancer cell lines) or DMEM (RAW 264.7) supplemented with 10% FBS (Gemini, Calabassas, CA), 2 mmol/L L-glutamine (Mediatech, Herndon, VA), 50 IU/mL penicillin (Mediatech), and 50 μg/mL streptomycin (Mediatech). RAW 264.7 was included in this study to determine if desialylation of gp96 affects its ability to bind to APC surface receptors. The cell lines were either subcultured or used for experimental procedures by trypsinization using 0.05% trypsin-EDTA (Mediatech) (prostate cancer cell lines) or cell scraping (RAW 264.7 . Tumors used to purify gp96 were obtained by xenografting human CaP cell lines (2 × 10 6 cells/mouse) in nude mice, whereas, MAT-LyLu (15,000 cells/rat) and Dunning G (2 × 10 6 cells/rat) tumors were grown by injecting the cell lines into syngeneic Copenhagen rats. Upon tumor growth, the animals were euthanized and the excised tumors were snap frozen in liquid nitrogen and subsequently stored at −80
• C until the need for gp96 purification.
Gp96 purification
Gp96 was purified from tissues as described earlier (Srivastava 1997; Zabrecky and Sawlivich 2004; Suriano et al. 2005) . Frozen tumor tissues (7 g) were pulverized using a mortar and pestle on liquid nitrogen followed by homogenization with a Brinkmann homogenizer in a solution of 30 mM HEPES, pH 7.2, containing 3.0 mM MgCl 2 and 0.2 M AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride). Tissue homogenates were then centrifuged at 7000 rpm (Beckman Ti-45 rotor) for 10 min after which the supernatant was centrifuged at 27,000 rpm (Beckman Ti-45 rotor) for 90 min. The supernatant was then subjected to a 50% ammonium sulfate precipitation for 2 h at 4
• C with constant stirring. Subsequently, the sample was centrifuged at 15,000 rpm and the resulting supernatant was subjected to an 80% ammonium sulfate precipitation for 12 h at 4
• C with constant stirring. The pellet obtained from the 80% ammonium sulfate precipitation was resuspended in ConA PBS (phosphate buffered saline, pH 7.0, containing 2 mM CaCl 2 and 2 mM MgCl 2 ) which was then applied to a 5 mL packed Concanavalin A (Con A)-Sepharose 4B (Pharmacia, Uppsala, Sweden) column previously equilibrated with 50 mL of ConA-PBS. Glycoproteins were eluted out with 10% methyl-α-D-mannose pyranoside (Sigma Chemical Company, St. Louis, MO) in ConA PBS. This high concentration of mannose (10%) used completely elutes out bound gp96. The ConA column eluate was then applied to PD-10 buffer exchange columns (Pharmacia) (2.5 mL/PD-10 column) which were pre-equilibrated with the 10 mM sodium phosphate buffer, pH 7.0, containing 300 mM NaCl. Proteins were eluted from the PD-10 columns with the 3.5 mL/column of 10 mM sodium phosphate buffer, pH 7.0, containing 300 mM NaCl. The PD-10 column eluates were then applied to a 5 mL DEAE-Sephacel (Pharmacia) column which was pre-equilibrated with the 10 mM sodium phosphate buffer, pH 7.0, containing 300 mM NaCl. Gp96 eluted in fractions 3 and 4 from the DEAE column among seven separate fractions (1.66 mL/fraction) collected using the 10 mM sodium phosphate buffer, pH 7.0, containing 700 mM NaCl as the elution buffer. Gp96 concentration was estimated from each of the seven fractions collected from the DEAE-Sephacel column using the Coomassie Plus TM Protein Assay (Pierce Chemical, Rockford IL). The purity of gp96 was checked resolving 5 μg of gp96 on a 12% SDS-PAGE gel. The gel was then stained with Coomassie Brilliant Blue R-250 (Bio-Rad, Hercules, CA)
LFA lectin analysis of gp96
Gp96 was resolved on a 12% SDS-PAGE and transferred on to a PVDF membrane. Ten micrograms of gp96 was resolved on SDS-PAGE. The membranes were subsequently blocked with 2% BSA in PBS-T at room temperature for 2 h. The membranes were subsequently incubated with 5 μg/mL of the horseradish peroxidase-labeled LFA lectin (EY Laboratories, San Mateo, CA) for 30 min at room temperature. The blots were washed three times with PBS-T (5 min/wash) and developed with the Super Signal R West Pico Chemiluminescent Substrate (Pierce Chemica).
Enzymatic desialylation of gp96
The terminal location of sialic or neuraminic acid on the glycan structure does not require acid hydrolysis as in monosaccharide analysis. The amino group on neuraminic acid can either be substituted with an acetyl or glycolyl group giving rise to Nacetylneuraminic acid (NANA) or N-glycolylneuraminic acid (NGNA) (Rohrer et al. 1998) . Both NANA and NGNA were detected by this analysis. Gp96 (40 μg) from LnCaP, DU145, MAT-LyLu, Dunning G, and normal rat prostate was incubated in 100 μL of PBS with 1 mU of Arthrobacter ureafaciens neuraminidase (Roche Diagnostics, Indianapolis, IN) for 24 h at 37
• C. The samples were then applied to a 30 kDa Microcon centrifugal device (Millipore, Bedford, MA) to separate protein from enzymatically cleaved sialic acid residues. Two hundred microliters of dH 2 O was then added to the filtrate and stored as −80
• C.
Sialic acid analysis of the gp96 glycans by HPAE-PAD
The filtrates were thawed and 50 μL of a 0.1 mM solution of KDN (3-deoxy-D-glycero-D-galacto-2-nonulosonic acid) (Toronto chemicals, Canada) was added. KDN is used as an internal standard which elutes between NANA and NGNA. The filtrates were then diluted 1:50 with dH 2 O. Twenty-five microliters of the filtrates were analyzed using the high pH anion exchange-pulse amperometric detection (HPAE-PAD) technique. The samples were injected into a DX-500 chromatographic system (Dionex Corporation, Sunnyvale, CA) using a 100 mM NaOH + 1 M sodium acetate solution as the elution buffer at the rate of 1 mL/min. The column used for NANA and NGNA separation was the PA-10 anion exchange column.
The sialic acid residues were then detected by the pulse amperometric ED50 detector. Quantitation of both NANA and NGNA, which was based on the chromatograms produced by the ED50 read-out of each gp96 filtrate, was by the Chromeleon (Dionex) software package. The chromatograms of the samples were compared and quantitated based on a reference chromatogram produced with 100 pmol of pure N-acetlyneuraminic acid (Sigma Chemical Company) and N-glycolylneuraminic acid (Sigma).
Gp96 binding to RAW 264.7 cell surface receptors
Binding of gp96 to cell surface receptors was modified from published reports (Binder et al. 2000a (Binder et al. , 2000b . A similar whole cell ELISA method was used to determine if gp96 (± sialic acid) binds to RAW 264.7 cell surface receptors. Briefly, 5 × 10 5 RAW 264.7 cells were incubated with 20 μg of gp96 for 2 h on ice. Following three washes with PBS containing 0.5% BSA, cells were then incubated with a rat anti-gp96 primary antibody (1:400) for 2 h. After three washes PBS containing 0.5% BSA, the cells were incubated with a HRP-conjugated anti-rat secondary antibody (1:10,000) for 2 h. Finally, the cells were washed three times and the HRP substrate OPD was added as described above. The absorbance was read using a Bio-Rad microplate reader at 490 nm with reference at 405 nm. The entire experiment was carried out on ice with the use of prechilled buffers so as to avoid receptor internalization due to ligand (gp96) binding.
Cytokine detection from Gp96 activated RAW 264.7 RAW 264.7 macrophages were harvested and pelleted as described. RAW 264.7 cells (1 × 10 6 /well) were seeded in 24 well plates (Becton Dickinson Labware, Lincoln Park, NJ) in a final volume of 500 μL of complete DMEM medium. The cells were allowed to adhere overnight. Forty micrograms of gp96 (Dunning G ± sialic acid) was added to the respective wells. In addition, 1 μg of E. coli lipopolysaccharides O111:B4 (LPS) (Sigma Chemical Company) was added to RAW 264.7 cells to serve as a positive control. The 24-well plate was then incubated for 24 h at 37
• C after which the cell culture supernatants were harvested and used for cytokine detection using a mouse cytokine antibody array (RayBiotech, Norcross, GA). Cytokine detection and relative levels were done according to the manufacturers specifications. The Gp96 used for the cytokine studies was purified from Dunning G tumors as described above with the exception that all buffers were made using endotoxin free water (<0.005 EU/mL) (HyClone Thermoscientific, South Logan, UT). Endotoxin levels in gp96 preparations were measured using the Limulus Amebocyte Lysate QCL-1000 assay (Cambrex, Walkersville, MD).
Funding
US Army Grant (W81XWH-06-1-0684 to R.K.T.).
Conflict of interest statement
None declared.
Abbreviations
AEBSF, ((4-(2-aminoethyl) benzenesulfonyl fluoride); APC, antigen presenting cell; ConA, concanavalin A; CTL, cytotoxic T lymphocyte; ER, endoplasmic reticulum; gp96, glycoprotein 96; HPAE-PAD, high pH anion exchange-pulsed amperometric detection; HSP, heat shock proteins; LAL, limulus amebocyte lysate; LFA, Limax flavus; NANA, N-acetylneuraminic acid; NGNA, N-glycolylneuraminic acid; SR-A, scavenger receptor A; TLR, toll-like receptor.
